SPERO THERAPEUTICS
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.
SPERO THERAPEUTICS
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.sperotherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+1 857 242 1600
Total Funding:
443.56 M USD
Technology used in webpage:
Domain Not Resolving Google Maps IPv6 COVID-19 DigiCert SSL Akamai Hosted RapidSSL
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
ForCast Orthopedics
ForCast Orthopedics, Inc is a medical device company with a significant goal to improve the treatment of orthopedic infections.
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Neurovirt Limited
VR software, hardware, mobile App
Relavo
Novel device to prevent infection in peritoneal dialysis, a form of at-home treatment for end-stage renal disease.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
ZeroIN
ZeroIn is foodtech company developing next-gen sweeteners to help food and beverage manufacturers reduce sugar in their products.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
GlaxoSmithKline
GlaxoSmithKline investment in Post-IPO Equity - Spero Therapeutics
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - Spero Therapeutics
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Spero Therapeutics
Pfizer
Pfizer investment in Post-IPO Equity - Spero Therapeutics
National Science Foundation
National Science Foundation investment in Grant - Spero Therapeutics
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Spero Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Post-IPO Equity - Spero Therapeutics
Cowen Investment Management
Cowen Investment Management investment in Post-IPO Equity - Spero Therapeutics
CARB-X
CARB-X investment in Grant - Spero Therapeutics
Google Ventures
Google Ventures investment in Series C - Spero Therapeutics
Key Employee Changes
Official Site Inspections
http://www.sperotherapeutics.com Semrush global rank: 1.1 M Semrush visits lastest month: 24.98 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Spero Therapeutics"
About Us | Spero Therapeutics
Our team is fueled by a passion for the communities we serve and guided by the profound meaning of the Latin word “spero,” which encapsulates our vision: to bring hope to patients and caregivers alike who are grappling with the …See details»
Meet Our Management Team | Spero Therapeutics
Meet the pioneers and emerging leaders in the anti-infective field at Spero Therapeutics. Get to know our experts in infectious disease treatment.See details»
Spero Therapeutics - Crunchbase Company Profile & Funding
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient …See details»
Spero Therapeutics - LinkedIn
Spero Therapeutics | 13,884 followers on LinkedIn. Multi-Asset, clinical-stage biotech company focused on multidrug-resistant bacterial infections and rare disease | We are a multi-asset, …See details»
Spero Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Spero Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 30 clinical trials, 116 news, and 40 literature, Disease Domain ...See details»
Spero Therapeutics Provides Business Update and Announces
Jan 10, 2025 Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership...See details»
Spero Therapeutics Provides Business Update and Announces …
Jan 10, 2025 Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the …See details»
Spero Therapeutics Provides Business Update and Announces …
Jan 10, 2025 [email protected]. Media Inquiries: Edelman Smithfield [email protected]. Spero Therapeutics [email protected] Markets …See details»
Working At Spero Therapeutics: Company Overview and Culture
Sperotherapeutics.com. Organization Type. Public. CEO. Ankit Mahadevia M.d. Social Media. Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative …See details»
Spero Therapeutics - VentureRadar
"Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) …See details»
About Us | Spero Therapeutics
Spero Therapeutics is dedicated to delivering differentiated medicines to help patients suffering from rare diseases and multidrug-resistant (MDR) bacterial infections.See details»
Spero Therapeutics Announces Interim Leadership Changes and
Jan 10, 2025 Esther Rajavelu appointed Interim CEO; Frank Thomas becomes Chairman amid SEC Wells Notice response; Phase 3 trial enrollment exceeds 60%. Spero Therapeutics …See details»
Investor Relations - Spero Therapeutics
Nov 14, 2024 We are committed to promoting a diverse workforce, where all employees feel respected, valued, and empowered to contribute to our mission. We are actively working to …See details»
Spero Therapeutics Announces Special Protocol Assessment …
Jul 31, 2023 Spero Therapeutics, Inc. Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023. Spero to receive $30 million development milestone payment …See details»
Spero Therapeutics Announces New Strategic Direction Focusing …
May 3, 2022 Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206 Spero to Explore Strategic …See details»
Spero Therapeutics Announces $40 Million Equity Investment
CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) – a multi-asset clinical-stage biopharmaceutical company focused on identifying, …See details»
Spero Therapeutics - PitchBook
Spero Therapeutics General Information Description. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel …See details»
Spero Therapeutics - Golden
Spero's lead product candidate is SPR994, which is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections, especially complicated …See details»
Biopharmaceutical Jobs at Spero Therapeutics
Our experienced and uniquely qualified team of biotechnology and biopharmaceutical experts is led by President and CEO, Sath Shukla. Openly transparent and highly respectful, our …See details»
Spero Therapeutics Announces SPR720 Phase 2a Interim Results …
Oct 29, 2024 Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on …See details»